Simplexia is a Project in the GU Ventures incubator, based on research resultas at the University of Gothenburg, developing a vaccine against herpes simplex virus type 2 (HSV-2) infection. HSV-2 is the most common sexually transmitted infection in the world and the infection causes genital herpes with painful and recurrent genital blisters. The virus can also cause life-threatening encephalitis and meningitis in newborns and immunocompromised patients. A major issue is that HSV-2 infected patients also suffer a three-fold increased risk of HIV acquisition.
Pls visit: http://simplexia.se/
Erik Dahlbergsgatan 11A, floor 2, SE-411 26 Gothenburg
+46 (0) 708-205555